MLM IT0001080248

End-of-day quote Borsa Italiana - 2020-09-27
0.5170	EUR		-.--%

2022	AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purification Technology and Contract Manufacturing Services for Antibody Therapies	CI
2022	RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies	CI
2021	AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility	CI

News

Most relevant

Official Publications

Sector news

Most relevant news about MOLMED S.P.A.

2022	AGC Biologics and W.L. Gore & Associates Collaborate on New Protein A-Based Purificatio..	CI
2022	RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell..	CI
2021	AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material..	CI
2020	MolMed Announces Transition of Luca Alberici from the Role of Chief Business Officer	CI
2020	Molmed S P A : CS_ integrativo del Comunicato dimissioni consiglieri	PU
2020	MolMed S.p.A.(BIT:MLM) dropped from S&P Global BMI Index	CI
2020	AGC Inc. completed the acquisition of 93.2% in MolMed S.p.A. from Finanziaria d'investi..	CI
2020	Orchard Therapeutics and MolMed Announce Extension of Gene Therapy Manufacturing Collab..	CI
2020	Italy to use vetting powers in Molmed acquisition by Japan's AGC	RE
2020	University Of Tartu : Novel DNA analysis will help to identify food origin and counterfeit..	AQ
2020	Karolinska Institutet : Overlooked protein could play important part in pneumonia and COVI..	AQ
2020	University Of Bristol : UK genome analysis has important implications for COVID-19 clinica..	AQ
2020	AGC Inc. entered into an agreement to acquire MolMed S.p.A. from Finanziaria d'investim..	CI
2020	Molmed S.P.A. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
2020	Molmed S P A : RhoVac announces appointment of Professor Anne J. Ridley to its Scientific ..	AQ
2019	Molmed S P A : UCT Shines At L'oréal-Unesco Sub-Saharan Africa	AQ
2019	Molmed S.P.A. Reports Earnings Results for the Third Quarter Ended September 30, 2019	CI
2019	Molecular Medicine : MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston	PU
2019	Molmed S.P.A. Reports Earnings Results for the Half Year Ended June 30, 2019	CI
2019	Molecular Medicine : MolMed announces the decision to suspend the enrollment of new patien..	PU
2019	Molecular Medicine : MolMed at the 22nd ASGCT congress on continuous innovation in the pro..	PU
2019	Molecular Medicine : Shareholders meeting approved the Financial Statement 2018. Incerti c..	PU
2019	Molecular Medicine : MolMed at the “Cell & Gene Meeting on the Med” conference..	PU
2019	Molecular Medicine : Notice of publication of the Annual Report 2018 and other documents (..	PU
2019	Molmed : Riccardo Palmisano reappointed representative of small and medium enterprises wit..	PU
2019	Molecular Medicine : MolMed received the authorization to start clinical investigation wit..	PU
2019	Molecular Medicine : Board of Directors approved 2018 Full Year financial results	PU
2019	Molecular Medicine : Partnership with Rocket Pharma in the field of rare genetic diseases ..	PU
2019	Molecular Medicine : MolMed and Genenta Science confirm and extend their partnership in th..	PU
2019	Molmed : the protocol of the in-man trial on CAR T CD44v6 presented at EHA (European Hemat..	PU
2019	Molecular Medicine : Opinion of the Commission HAS on Zalmoxis® reimbursability in France	PU
2018	Molecular Medicine : PR_Publication of the minutes of Shareholders Meeting of Oct 25 and o..	PU
2018	Molecular Medicine : Interim financial results as of September 30th 2018	PU
2018	Molecular Medicine : MolMed and Dompé mutually terminate the license and distribution agre..	PU
2018	Molmed S.P.A. Reports Earnings Results for Third Quarter and Nine Months Ended Septembe..	CI
2018	Molecular Medicine : October 25th 2018 Ordinary and Extraordinary Shareholders Meeting Out..	PU
2018	Molecular Medicine : A new study confirms the high potential of on CAR T CD44v6 also in so..	PU
2018	Molmed : announcement with reference to the shareholders meeting of October 25th 2018.	PU
2018	Molecular Medicine : Carlo Incerti succeeds to Claudio Bordignon as Chairman of the Board...	PU
2018	Molecular Medicine : MolMed appoints Mr. Salvatore Calabrese Chief Financial Officer	PU
2018	Molecular Medicine : Publication of the Interim Financial Report at June 30th 2018	PU
2018	Molecular Medicine : MolMed signs a new, three-year agreement for the development and supp..	PU
2018	Molecular Medicine : Resignation of the Officer Responsible for the preparation of financi..	PU
2018	MolMed S.p.A. and AbCheck s.r.o. Sign A Three-Year Master Agreement for the Development..	CI
2018	Molecular Medicine : New and relevant data on the therapeutic potential of NGR-hTNF in bra..	PU
2018	Molecular Medicine : MolMed and Glycostem announce the execution of a binding termsheet fo..	PU
2018	Molecular Medicine : Further data on the safety of CAR-T CD44v6 result from a study by S. ..	PU
2018	Molecular Medicine : 5th tranche of the share capital increase reserved to Société Général..	PU
2018	Molecular Medicine : Utilization request concerning the 5th tranche of the share capital i..	PU
2018	Molecular Medicine : Full results of NGR-hTNF trial in mesothelioma published by The Lance..	PU
2018	MolMed S.p.A. Announces Earnings Results for the First Quarter Ended March 31, 2018	CI
2018	Molecular Medicine : Publication of the minutes of Shareholders Meeting of April 12nd 2018	PU
2018	Molecular Medicine : MolMed signs Master Service Agreement with Boston Children's Hospital..	PU
2018	Molmed : the Shareholders' Meeting approves 2017 Financial Statements	PU
2018	Molecular Medicine : MolMed and Orchard Therapeutics announce the beginning of their colla..	PU
2018	MolMed S.p.A. Reports Earnings Results for the Full Year Ended of December 31, 2017	CI
2018	Molmed And Miltenyi Biotec : EMA approves the utilization of the CliniMACS Prodigy® equipm..	PU
2018	Molmed : AIFA Determina on reimbursement regime and market price for the proprietary cell ..	PU
2018	Molmed : Dompé exercises the option right to undertake the market access and commercializa..	PU
2018	Zalmoxis® : price & reimbursement in Germany, where the product can be prescribed and reim..	PU
2017	Molecular Medicine : AIFA set the reimbursement price for Zalmoxis® at EUR 149.000 per inf..	PU
2017	Molecular Medicine : Board of Directors examined the business performance and approved the..	PU
2017	Molmed S.P.A. Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..	CI
2017	Molecular Medicine : New relevant safety data of CD44v6 CAR-T cells will be presented at t..	PU
2017	MolMed S.p.A. announced that it has received funding from Société Générale Capital Part..	CI
2017	Molecular Medicine : MolMed will attend the 2nd EBMT INTERNATIONAL TRANSPLANT COURSE in Ba..	PU
2017	Molmed : submitted the utilization request concerning the second tranche of the share capi..	PU
2017	Molecular Medicine : MolMed and Cellectis signed a development and manufacturing agreement..	PU
2017	MolMed S.p.A. Announces Earnings Results for the Six Months Ended June 30, 2017	CI
2017	Molecular Medicine : MolMed and Dompé signed strategic commercialization and supply agreem..	PU
2017	Molmed S.p.a. : mandate of Liquidity Provider assigned to Mediobanca	PU
2017	MolMed S.p.A. and TTY Biopharm Company Ltd Announce Exclusive License and Distribution ..	CI
2017	Molecular Medicine : MolMed provides update on Zafiride Conditional Marketing Authorizatio..	PU
2017	MolMed S.p.A. Reports Earnings Results for the First Quarter Ended March 31, 2017	CI
2017	Megapharm Enters into Distribution and Licensing Agreement with MolMed for Zalmoxis	CI

1 2 3 Next

Upcoming sector events

02/09/23	ALNYLAM PHARMACEUTICALS, INC. : FY 2022 Earnings Release (Projected)
02/10/23	IQVIA HOLDINGS INC. : FY 2022 Earnings Release
02/15/23	SEAGEN INC. : FY 2022 Earnings Release
02/23/23	MODERNA, INC. : FY 2022 Earnings Release (Projected)

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Other Biotechnology & Medical Research